Black Diamond Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Black Diamond Therapeutics has a total shareholder equity of $116.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $158.6M and $41.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$131.40m |
| Equity | US$116.74m |
| Total liabilities | US$41.83m |
| Total assets | US$158.57m |
Recent financial health updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02Recent updates
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Financial Position Analysis
Short Term Liabilities: BDTX's short term assets ($134.0M) exceed its short term liabilities ($19.6M).
Long Term Liabilities: BDTX's short term assets ($134.0M) exceed its long term liabilities ($22.2M).
Debt to Equity History and Analysis
Debt Level: BDTX is debt free.
Reducing Debt: BDTX has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BDTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BDTX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 29.1% each year.